Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (5.998.753 €): ATRIAL FIBRILLATION INTEGRATED APPROACH IN FRAIL, MULTIMORBID, AND POLYMEDICATED OLDER PEOPLE Hor 12.02.2021 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
ATRIAL FIBRILLATION INTEGRATED APPROACH IN FRAIL, MULTIMORBID, AND POLYMEDICATED OLDER PEOPLE
Multimorbidity is a common condition in older age, and can substantially influence individuals’ health and quality of life, making management more difficult. A single-disease approach with fragmented care is still prevalent in current healthcare systems despite multimorbidity representing a heterogeneous spectrum of disease combination(s). On this background, the novel approach underpinning the AFFIRMO project is to focus on clusters of multimorbidity where atrial fibrillation(AF) represents one of the chronic conditions. Improving the management of AF in the context of multimorbidity may benefit individuals on a larger scale, with a holistic approach to optimize clinical management of older AF patients taking into account the multifaceted aspects of individuals’ health, including multimorbidity, polypharmacy, personal preferences, and social context. First, the project aims to identify different clusters of multimorbidity in older patients with AF. Second, AFFIRMO aims to assess the needs of patients, caregivers, and health professionals for the comprehensive management of multimorbidity including AF, and to examine ways of optimizing care and self-management. Third, AFFIRMO will develop, implement and test the effectiveness of a patient-centered approach on older multimorbid AF patients in the clinical practice. We aim to adapt, implement and promote a care pathway, in older patients with multimorbidity. A specific objective will be to develop an interoperable care framework that can facilitate the application of this personalized care pathway, that bridges the continuum between primary and secondary care, with the active involvement of patients with shared decision-making. A further aim will be to model the impact of multimorbidity including AF on healthcare costs and the health economic benefits by the proposed integrated care pathway. Finally, subgroup analyses would assess differences on outcomes of in relation to gender and social inequalities.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Aalborg Universitet | 809.487 € |
| Advice Pharma Group Srl | 89.914 € |
| Arrhythmia Alliance | 25.000 € |
| Consiglio Nazionale Delle Ricerche | 73.190 € |
| European Union Geriatric Medicine Society Aisbl | 102.875 € |
| Faculty OF Medicine, University OF Belgrade | 140.750 € |
| HCF Fondazione Anmco Per IL TUO Cuore ETS | 651.000 € |
| Istituto Superiore Di Sanita | 129.895 € |
| Karolinska Institutet | 506.278 € |
| Meditcinsky Universitet-Plovdiv | 146.250 € |
| Moverim Srl | 188.645 € |
| Ontonix Srl | 116.000 € |
| THE European Institute for Innovation Through Health Data | 212.441 € |
| The University of Liverpool | 621.888 € |
| The University of Manchester | 807.738 € |
| Universidad de Murcia | 378.504 € |
| Universita Cattolica Del Sacro Cuore | 250.513 € |
| Universita Degli Studi Di Padova | 143.875 € |
| Universitatea de Medicina si Farmacie Carol Davila Din Bucuresti | 147.013 € |
| Universiteit Gent | 457.500 € |
Quelle: https://cordis.europa.eu/project/id/899871
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.